🇯🇵·12h agoIndustry
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
Publisher
O
Otsuka Pharmaceutical
Japan
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Otsuka Pharmaceutical
- Region
- Japan
- Scope
- Industry
- Published
- September 24, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on otsuka.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Otsuka Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News/2h ago
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Interpharma Switzerland/6h ago
Klinische Forschung unter Druck: Die Schweiz verliert den Anschluss
Chugai Pharmaceutical News/6h ago
ロシュ社によるセーファキセルセンナトリウムに関する発表について（第III相IMAGINATION試験の中間解析結果）
Chugai Pharmaceutical/6h ago